Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CHRH1HTR2AHTR2C
The experimentally established mechanism targets of Esmirtazapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 8/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 6/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 1.00 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 1.00 |
| ▸ | DRD3 | P35462 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 5/20 | 1.00 |
| ▸ | HTR3A | P46098 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mirtazapine SCHEMBL35408 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Mirtazapine SCHEMBL29484433 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Mirtazapine SCHEMBL29579914 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Mirtazapine SCHEMBL966891 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Esmirtazapine SCHEMBL29579803 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Mirtazapine SCHEMBL8271559 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Mirtazapine SCHEMBL5666018 | 0.99 | HTR2A (0.97) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Mirtazapine SCHEMBL355514 | 0.99 | HTR2A (0.97) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Mirtazapine SCHEMBL5586522 | 0.99 | HTR2A (0.97) | HTR2AHTR2CHTR2BDRD3HTR1A | |
| Mirtazapine SCHEMBL2483266 | 0.99 | HTR2A (0.97) | HTR2AHTR2CHTR2BDRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5896 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250255823-A1 | COMPOSITION AND METHOD FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS | DUKE UNIVERSITY (US) | 2025-08-14 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250177376-A1 | ALPHA 2 ADRENERGIC RECEPTOR BLOCKADE FOR THE TREATMENT OF C. DIFFICILE COLITIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-06-05 | — | — | US | claimed |
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| WO-2003022283-A1 | COMBINATION OF AN ADENOSINE A2A RECEPTOR ANTAGONIST AND AN ANTIDEPRESSANT OR ANXIOLYTIC | SCHERING CORPORATION (US) | 2003-03-20 | — | — | WO | claimed |
| US-20030032636-A1 | Combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist | H. LUNDBECK A/S (DK) | 2003-02-13 | — | — | US | claimed |
| EP-1272181-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | Synthon B.V. (NL) | 2003-01-08 | — | — | EP | claimed |
| WO-2002094232-A1 | DELIVERY OF ANTIDEPRESSANTS THROUGH AN INHALATION ROUTE | ALEXZA MOLECULAR DELIVERY CORPORATION (US) | 2002-11-28 | — | — | WO | claimed |
| US-6458384-B2 | MODIFYING THE EFFECT OF A FIRST DRUG BY ADDING A SECOND DRUG; SOPORIFIC AGENT AND A STIMULANT FOR EXAMPLE | IMPETUS AG (CH) | 2002-10-01 | — | — | US | claimed |
| EP-1237553-A2 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT 2C? ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST | H. LUNDBECK A/S (DK) | 2002-09-11 | — | — | EP | claimed |
| US-20010038863-A1 | Pharmaceutical with predetermined activity profile | INQPHARM GROUP SDN BHD (MY) | 2001-11-08 | — | — | US | claimed |
| WO-2001078725-A2 | MODIFIED RELEASE FORMULATIONS CONTAINING A HYPNOTIC AGENT | SYNTHON B.V. (NL) | 2001-10-25 | — | — | WO | claimed |
| WO-2001041701-A2 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A 5-HT2C ANTAGONIST, INVERSE AGONIST OR PARTIAL AGONIST | H. LUNDBECK A/S (DK) | 2001-06-14 | — | — | WO | claimed |
| EP-0431663-B1 | Stabilized solutions of psychotropic agents | AKZO NV (NL) | 1994-01-12 | — | — | EP | claimed |